Healthcare
Integra LifeSciences Holdings Corporation(IART)
Live Price
Offline$17.20
-2.88% today
1Y Change
+44.90%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $820.00M
- Revenue Growth
- +1.5%
- EPS Growth
- -7361.2%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Integra LifeSciences Holdings Corporation (IART) is a Healthcare stock with a market cap of $820.00M and listed on NASDAQ. The stock last traded around $17.20 and up 44.9% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +1.5%, EPS growth of -7361.2%, a dividend yield of 0.0%. What stands out right now is revenue +1.5%, EPS -7361.2%, free cash flow -224.4% with operating margin 4.2% and ROIC 1.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IART price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.5% vs +7.6% peer median
Operating Margin
Below sector median
+4.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +1.5% and EPS is at -7361.2%, with operating margin around 4.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +24.1% | +31.2% | +47.1% |
2026 Feb 26, 2026 | +5.1% | +0.4% | -12.7% | -17.2% |
2025 Oct 30, 2025 | +25.6% | +1.7% | -5.0% | +11.1% |
Benchmark Edge
IART vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IART
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IART Max Drawdown
-44.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IART and SPY.
Company Overview
Integra LifeSciences Holdings Corporation
NASDAQ Global Select
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
- Leadership
- Mojdeh Poul
- IPO Date
- Aug 16, 1995
- Employees
- 4.4k
- Street Address
- 1100 Campus Road
- Mailing
- Princeton, NJ, 08540
- Region
- Princeton, NJ, US
- Reporting Currency
- USD
- Investor Line
- 609 275 0500
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- 0.8
Growth
- Revenue
- +1.5%
- EPS
- -7361.2%
- Free Cash Flow
- -224.4%
Profitability
- Gross Margin
- 51.7%
- Operating Margin
- 4.2%
- Net Margin
- -31.6%
- ROE
- -44.5%
- ROIC
- 1.9%
Balance Sheet
- Debt/Equity
- 1.95
- Current Ratio
- 2.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.